463 related articles for article (PubMed ID: 17003520)
1. Interplay between the p53 tumor suppressor protein family and Cdk5: novel therapeutic approaches for the treatment of neurodegenerative diseases using selective Cdk inhibitors.
Schmid G; Strosznajder JB; Wesierska-Gadek J
Mol Neurobiol; 2006 Aug; 34(1):27-50. PubMed ID: 17003520
[TBL] [Abstract][Full Text] [Related]
2. Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin.
Wesierska-Gadek J; Gueorguieva M; Horky M
Pol J Pharmacol; 2003; 55(5):895-902. PubMed ID: 14704484
[TBL] [Abstract][Full Text] [Related]
3. Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the Cdk5 inhibitory peptide.
Kesavapany S; Li BS; Amin N; Zheng YL; Grant P; Pant HC
Biochim Biophys Acta; 2004 Mar; 1697(1-2):143-53. PubMed ID: 15023357
[TBL] [Abstract][Full Text] [Related]
4. p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway.
Patrick GN; Zhou P; Kwon YT; Howley PM; Tsai LH
J Biol Chem; 1998 Sep; 273(37):24057-64. PubMed ID: 9727024
[TBL] [Abstract][Full Text] [Related]
5. p39 Is Responsible for Increasing Cdk5 Activity during Postnatal Neuron Differentiation and Governs Neuronal Network Formation and Epileptic Responses.
Li W; Allen ME; Rui Y; Ku L; Liu G; Bankston AN; Zheng JQ; Feng Y
J Neurosci; 2016 Nov; 36(44):11283-11294. PubMed ID: 27807169
[TBL] [Abstract][Full Text] [Related]
6. The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator.
Hisanaga S; Saito T
Neurosignals; 2003; 12(4-5):221-9. PubMed ID: 14673209
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of cyclin-dependent kinase 5 (Cdk5) at Tyr-15 is inhibited by Cdk5 activators and does not contribute to the activation of Cdk5.
Kobayashi H; Saito T; Sato K; Furusawa K; Hosokawa T; Tsutsumi K; Asada A; Kamada S; Ohshima T; Hisanaga S
J Biol Chem; 2014 Jul; 289(28):19627-36. PubMed ID: 24872417
[TBL] [Abstract][Full Text] [Related]
8. Influence of phosphorylation of p35, an activator of cyclin-dependent kinase 5 (cdk5), on the proteolysis of p35.
Kerokoski P; Suuronen T; Salminen A; Soininen H; Pirttilä T
Brain Res Mol Brain Res; 2002 Oct; 106(1-2):50-6. PubMed ID: 12393264
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
[TBL] [Abstract][Full Text] [Related]
10. Cdk5/p35 regulates neurotransmitter release through phosphorylation and downregulation of P/Q-type voltage-dependent calcium channel activity.
Tomizawa K; Ohta J; Matsushita M; Moriwaki A; Li ST; Takei K; Matsui H
J Neurosci; 2002 Apr; 22(7):2590-7. PubMed ID: 11923424
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinase 5--a neuronal killer?
Guo Q
Sci Aging Knowledge Environ; 2003 Dec; 2003(50):pe36. PubMed ID: 14681576
[TBL] [Abstract][Full Text] [Related]
12. Regulation and role of cyclin-dependent kinase activity in neuronal survival and death.
Hisanaga S; Endo R
J Neurochem; 2010 Dec; 115(6):1309-21. PubMed ID: 21044075
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of aberrant cyclin-dependent kinase 5 activity attenuates isoflurane neurotoxicity in the developing brain.
Wang WY; Luo Y; Jia LJ; Hu SF; Lou XK; Shen SL; Lu H; Zhang HH; Yang R; Wang H; Ma ZW; Xue QS; Yu BW
Neuropharmacology; 2014 Feb; 77():90-9. PubMed ID: 24055498
[TBL] [Abstract][Full Text] [Related]
14. A review on cyclin-dependent kinase 5: An emerging drug target for neurodegenerative diseases.
Batra S; Jahan S; Ashraf A; Alharby B; Jawaid T; Islam A; Hassan I
Int J Biol Macromol; 2023 Mar; 230():123259. PubMed ID: 36641018
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
16. The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology.
Maccioni RB; Otth C; Concha II; Muñoz JP
Eur J Biochem; 2001 Mar; 268(6):1518-27. PubMed ID: 11248668
[TBL] [Abstract][Full Text] [Related]
17. Cdk5 phosphorylates p53 and regulates its activity.
Zhang J; Krishnamurthy PK; Johnson GV
J Neurochem; 2002 Apr; 81(2):307-13. PubMed ID: 12064478
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of p35 and p39 by Cdk5 determines the subcellular location of the holokinase in a phosphorylation-site-specific manner.
Asada A; Saito T; Hisanaga S
J Cell Sci; 2012 Jul; 125(Pt 14):3421-9. PubMed ID: 22467861
[TBL] [Abstract][Full Text] [Related]
19. The role of CDK5/P25 formation/inhibition in neurodegeneration.
Camins A; Verdaguer E; Folch J; Canudas AM; Pallàs M
Drug News Perspect; 2006 Oct; 19(8):453-60. PubMed ID: 17160145
[TBL] [Abstract][Full Text] [Related]
20. An unusual member of the Cdk family: Cdk5.
Dhariwala FA; Rajadhyaksha MS
Cell Mol Neurobiol; 2008 May; 28(3):351-69. PubMed ID: 18183483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
